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Abstract 
Introduction: The association between cigarette smoking and schizophrenia is well 
established. However, up to 90% of people with schizophrenia begin smoking before the 
onset of their illness, thus smoking could be an independent risk factor for schizophrenia. 
Prenatal exposure to maternal cigarette smoke is also associated with psychiatric problems in 
adolescence. Therefore, our aim was to undertake a systematic review and meta-analysis to 
explore the effect of smoking, and prenatal smoke exposure, on risk of schizophrenia.  
Method: We systematically searched Medline, Embase, PsychInfo, Maternity and Infant 
Care, and Web of Science (from inception to February 2018) to identify comparative 
observational studies of the risk of schizophrenia in relation to smoking status. Measures of 
Relative Risk (RR) were pooled in a meta-analysis with 95% confidence intervals, using 
random effects model. 
Results: Twelve studies (9 cohort, 3 case-control) were included. Odds ratios (OR) and 
hazard ratios (HR) were pooled together to estimate pooled RRs and estimates combined in a 
meta-analysis on an assumption of constant risk over time. Smokers had a significantly 
increased risk of schizophrenia compared to non-smokers (RR 1.99, 95% CI 1.10-3.61, I2= 
97%, 5 studies). Exposure to prenatal smoke increased the risk of schizophrenia by 29% 
(95% CI 1.10-1.51, I2= 71%, 7 studies). Sensitivity analyses identified no significant 
differences between the results from studies reporting OR and HR. 
Conclusions: Our findings suggest smoking, and prenatal smoke exposure, may be an 
independent risk factor for schizophrenia. Care should be taken when inferring causation, 
given the observational nature of the studies.  
 
Implications 
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In this meta-analysis of 12 studies smokers had a significantly increased risk of schizophrenia 
compared to non-smokers. Exposure to prenatal tobacco smoke also increased the risk of 
schizophrenia by 29% compared to those with no exposure to prenatal tobacco smoke. Our 
findings suggest that smoking, and prenatal tobacco smoke exposure, may be independent 
risk factors for schizophrenia. These results may have important public health implications 
for decreasing the incidence of schizophrenia. The possibility of a causal link between 
smoking and schizophrenia warrants further investigation.  
 
Introduction 
Smoking is associated with an increased risk of many health conditions 1, and is particularly 
common among people with mental health problems 2, but the causal nature of the 
association between smoking and mental illness remains uncertain. In particular, it is unclear 
whether the high prevalence of smoking among people with schizophrenia 3 arises from a 
direct causal effect of smoking on the disease, or reverse causation from the use of nicotine to 
self-medicate psychotic symptoms 4. Since 90% of people with schizophrenia begin smoking 
before the onset of their illness 5-7 this suggests that smoking may increase the risk of 
schizophrenia; however, evidence of cognitive improvements in people with schizophrenia 
following smoking 8 9 supports the self-medication hypothesis.  Furthermore it is possible that 
maternal smoking is associated with an increased risk of schizophrenia in offspring, since 
prenatal exposure to maternal cigarette smoke has been shown to be associated with 
psychiatric and behavioural problems in adolescence 10-12 and in adulthood 13-15.  
 
In view of this uncertainty we have carried out a systematic review to search the international 
literature for comparative observational studies of smoking and incident schizophrenia, 
including both personal active smoking and passive exposure to the foetus arising from 
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maternal smoking in pregnancy, and used meta-analysis to estimate contemporary risks of 
schizophrenia.  
 
Methods 
Our methods followed the EQUATOR (Enhancing the quality and transparency of health 
research) reporting guidelines and included MOOSE (Meta-analysis of Observational Studies 
in Epidemiology) Guidelines 16 on reporting meta-analyses of observational studies, and the 
PRISMA (Preferred reporting items for systematic reviews and meta-analyses) statement 17. 
Our review protocol was registered at PROSPERO (http://www.crd.york.ac.uk/PROSPERO), 
registration number CRD42017064459. 
 
Inclusion criteria and search strategy 
We included all cohort (retrospective and prospective) and case-control epidemiologic studies 
assessing the association between tobacco smoking, or maternal prenatal tobacco smoke 
exposure and risk of schizophrenia. We included studies that used ICD, DSM or other 
standardised diagnostic criteria for schizophrenia. We included studies that used any self-
reported or biochemically validated measure of smoking, and we included any schizophrenia 
spectrum disorders (schizophrenia, schizoaffective disorder and schizotypal disorder). Studies 
in which tobacco use could not be distinguished from use of other substances e.g. cannabis, 
were excluded, as were studies in which schizophrenia could not be distinguished from 
bipolar disorder or other diagnosis. The databases Medline (accessed via Ovid), EMBASE 
(accessed via Ovid), PsychInfo, Maternity and Infant Care Database, and Web of Science, 
were searched between database inception and February 2018. Search keywords were 
determined from the Cochrane review group terms for tobacco 18 and schizophrenia 19, and 
the BMJ Clinical Evidence study design search filters 20. The search strategy was specified to 
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capture all potentially eligible records relating to smoking and schizophrenia. The lead author 
developed the search strategy, with input from The University of Nottingham library support 
team. A combination of Medical Subject Headings (MeSH) and relevant text words were 
used wherever possible. An example of the search criteria used for Ovid Medline can be 
found in Supplementary Table 1. We also searched the reference lists of included studies, and 
review articles that had been identified in the search. No language restrictions were applied in 
the search, and where possible, studies were translated. 
 
Screening of the studies 
We used Covidence software 21 to manage the data screening process. Two authors (AH and 
RM) independently reviewed the titles and abstracts, and then full text to identify potentially 
eligible articles. Full text copies of papers were then obtained for all those considered 
potentially relevant or for which there was insufficient information in the title and abstract to 
make a firm decision. Any discrepancies at each step were resolved by discussion.  
 
Data extraction 
Data extraction was carried out independently by two authors (AH and RM) using a 
previously piloted form. Key data extracted included details of the study design, methods, 
diagnostic criteria for schizophrenia, measurement of smoking status, geographic location, 
reference population, number of people recruited, participant characteristics (age, gender), 
length of follow up, and results.  
 
Quality assessment 
Included articles were independently scored by two authors (AH and RM) for methodological 
quality using the Newcastle-Ottawa Quality Assessment Scale (NOS) 22. This scale awards 
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points for representativeness of the cohort, selection of the non-exposed cohort, 
ascertainment of exposure/ outcome, adjustment for confounders in the analyses (e.g. age, 
gender, substance abuse) and follow-up (length and completeness). A separate scale specific 
for case-control studies was used which awards points for representativeness of the cases, 
definition of case and controls, selection of controls, comparability of cases and controls, 
ascertainment of exposure, and non-response rate. Both scales have a maximum score of nine 
points; a high quality study was deemed to be identified by a score of at least seven. Any 
disagreement between the reviewers was resolved through discussion.   
 
Statistical analysis  
Crude measures of effect or adjusted measures of effect were extracted from the individual 
studies. Where adjusted measures were available, these were used in preference. Effect 
measures were extracted as odds ratios (OR), or hazard ratios (HR), with 95% confidence 
intervals (CI). Where more than two categories of level of cigarette consumption were 
reported in a study, we extracted adjusted effect measures relating to a comparison of the 
highest to the lowest exposure group.  
 
Pooled measures of effect across studies were estimated using random effects meta-analysis 
using the generic inverse variance method to weight the studies. Due to inherent biases in 
observational study designs, it was deemed appropriate to use a random effects model. We 
pooled odds ratios and hazard ratios together to estimate pooled Relative Risks (RRs). We 
combined these estimates in a meta-analysis on an assumption of constant risk over time, and 
acknowledge that, despite schizophrenia being a rare disease, the odds ratios will slightly 
overestimate the true relative risk. Additionally, the event rate in the exposed and unexposed 
groups was low (<10%), also justifying our decision to pool hazard ratios with odds ratios.  
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Heterogeneity between the studies was quantified using I2 23. Heterogeneity was anticipated 
due to the diverse methodological and clinical nature of the studies 23. We performed a 
sensitivity analysis excluding studies which reported hazard ratios from the meta-analysis to 
assess the magnitude of the pooled results. Sensitivity analyses were also conducted to assess 
the robustness of the results based on study design. Due to the small number of studies, only 
a limited number of sub-group analysis could be performed (study quality and schizophrenia 
diagnostic criteria). We were unable to perform subgroup analysis based on country (high vs 
low/middle income) as all studies were from high income countries. As we had fewer than 10 
studies for each meta-analysis, it was not possible to visually assess evidence of publication 
bias using funnel plots, as the test power would be too low to distinguish chance from real 
asymmetry 24. Descriptive analysis was undertaken to explore the dose response relationship 
between cigarette consumption and schizophrenia in those studies that reported different 
levels of cigarette consumption. Review Manager (version 5.3) was used to perform analyses. 
P values < 0.05 were taken to represent statistical significance.  
 
Results  
Overview of the included studies 
The systematic search of electronic databases identified 7,919 articles (Figure 1). After 
duplicates were removed, 5,742 articles were screened by title and abstract, and 107 full texts 
were retrieved to assess eligibility. Of these, 95 were ineligible on the grounds of outcome 
(n=55), study design (n=15), exposure definitions (n=11), opinion piece (n=10) or because 
we were unable to locate the full text in any language (n=2), or were unable to translate the 
text into English (n=2). One article was translated from French 25 and subsequently excluded 
based on study design. A number of review articles (26-38) were identified in the search, and 
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the reference lists of these, along with the included studies, were hand searched. An 
additional four articles were identified but after full text screening these were ineligible 
(included in Figure 1). Twelve articles were eligible for inclusion in the systematic review 
(five were concerned with personal active smoking; seven were concerned with maternal 
prenatal tobacco smoke exposure). Supplementary Table 2 summarises the study 
characteristics of the included studies.    
 
INSERT FIGURE 1 
 
Methodological quality of the studies 
The methodological quality of the twelve included studies are presented in Supplementary 
Table 2. The quality assessment scores ranged from 4 to 9. The median quality score was 7.5, 
indicating that the overall methodological quality was good, with 67% of the studies scoring 
7 or more. The main reason for lower quality scores was lack of information on confounding 
variables adjusted for, and the use of self-reported rather than objectively validated smoking 
status (only one study provided objective data in the form of cotinine levels 39). All studies 
scored high on outcome, as schizophrenia was clinically diagnosed and linked to medical 
records. The majority of the studies diagnosed schizophrenia according to ICD criteria, three 
used DSM diagnostic criteria 40-42, and one used the Present State Examination 43.  
 
Personal active smoking 
Five cohort studies reported data on the association between schizophrenia and smoking, 
published between 2003 and 2015. Two studies each were from Denmark 44 45 and Sweden 4 
46, and one study from Israel 47. Two studies included males only 4 47, one included females 
only 44, one included males and females 46, and one did not report gender 45 but was assumed 
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to include males and females as they recruited from both the Copenhagen General Population 
Study and the Copenhagen City Heart Study. The total number of participants in each study 
ranged from 7,926 44  to 1,647,728 46, and in total the five studies included 1,783,251 
participants and 2,028 people with schizophrenia (although Kendler, et al. [46] only reported 
the number of females with schizophrenia, and not males). The follow up period ranged from 
4 years 47 to 40 years 44. Table 1 presents the odds ratios and 95% confidence intervals for 
unadjusted and adjusted estimates where available, for all studies.   
 
INSERT TABLE 1 
 
A pooled analysis of the five studies found the combined estimate of effect was a relative risk 
of 1.99 (95% CI 1.10 to 3.61; I2=97%, 5 studies; Figure 2). Results from a sensitivity analysis 
restricted to studies reporting odds ratios were similar (Relative Risk = 2.81, 95% CI 0.67-
11.84; I2=92%, 2 studies), suggesting the findings were robust. Subgroup analysis within the 
five studies reporting the association between smoking and schizophrenia found that study 
quality (high versus low-medium; p=0.14) did not explain high level of heterogeneity 
(Supplementary Figure 1). There was insufficient data to perform further subgroup analysis.  
 
Descriptive analysis was undertaken to explore the dose response relationship between 
cigarette consumption and schizophrenia. All five studies looking at the effect of personal 
active smoking on the risk of schizophrenia reported different levels of smoking (see 
Supplementary Table 3). There was evidence from four studies to suggest that heavier 
smoking was associated with greater risk for schizophrenia. Weiser and colleagues 47 found a 
significant linear association between the number of cigarettes smoked and the risk of 
schizophrenia, with those who smoked 10 cigarettes a day or more, 2.28 times (95% 
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CI=1.19-4.34; Wald 2=6.22, d.f=1, p=0.02) more likely to be hospitalised later for 
schizophrenia. Sorenson and colleagues 44 also found a significant linear effect of smoking 
(OR=1.18 (1.07-1.30)). Wium-Anderson and colleagues 45 found that increasing number of 
pack years was associated with schizophrenia (OR=4.13 (1.61-10.60) for participants with 
>40 pack-years vs never smokers. Kendler and colleagues 46 also found a clear dose-response 
relationship between number of cigarettes smoked and risk of schizophrenia, and that the risk 
for schizophrenia was more strongly associated with heavy than with light smoking in both 
males (OR=2.21 (1.11-4.42)) and females (OR=2.77 (2.34-3.43)). One further study found 
that cigarette smoking at age 18 was associated with a lower risk of developing schizophrenia 
in both medium and heavy smokers compared to non-smokers, with an adjusted hazard ratio 
for linear trend across the four smoking categories of 0.8 (95% CI=0.7-0.9, p=0.002)4.  
 
 
INSERT FIGURE 2 
 
Prenatal tobacco smoke exposure 
Seven studies reported data on the association between schizophrenia and prenatal tobacco 
smoke exposure 39-43 48 49, published between 1995 and 2017. Two studies were from Finland 
39 42, and one study each from Great Britain 43, France 40, Greece 41, Denmark 48 and Sweden 
49. Four were cohort studies, and three were case-control studies. Five studies included males 
and females 39-42 49. Two studies did not explicitly report gender 43 48. The total number of 
participants in each study ranged from 200 40 to 1,680,219 49, and in total the seven studies 
included 2,444,910 participants and 10,278 people with schizophrenia. The follow up period 
ranged from 11 years 39 to 31 years 49.  
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A pooled analysis of the seven studies found that those who had been exposed to maternal 
prenatal smoke had a 29% increased risk of developing schizophrenia (RR= 1.29, 95% CI 
1.10 to 1.51; I2=71%, 7 studies; Figure 3). Results from a sensitivity analysis restricted to 
studies reporting odds ratios were similar (Relative Risk = 1.34, 95% CI 0.90-1.98; I2=59%, 5 
studies), suggesting the findings are robust.  
 
INSERT FIGURE 3 
 
Subgroup analysis of the studies reporting the association between maternal prenatal smoke 
exposure and schizophrenia found that study quality (high versus low-medium; p=0.53; 
Supplementary Figure 2), and schizophrenia diagnostic criteria (International Classification 
of Diseases (ICD) vs Diagnostic Statistical Manual (DSM)/Present State Examination; 
p=0.99; Supplementary Figure 3) did not explain the high level of heterogeneity. There was 
insufficient data to perform further subgroup analysis.  
 
Descriptive analysis was undertaken to explore the dose response relationship between 
maternal cigarette consumption and schizophrenia. Two studies reported different levels of 
exposure to prenatal maternal smoke 39 49 (see Supplementary Table 3), however, no dose-
response relationship was observed.  
 
Discussion 
This systematic review and meta-analysis of observational studies reporting the risk of 
schizophrenia in smokers has indicated an approximated doubling of the risk of schizophrenia 
among smokers relative to non-smokers. We also found evidence of a statistically significant 
increase in risk of schizophrenia among offspring of those whose mothers smoked during 
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pregnancy compared to those whose mothers who did not smoke during pregnancy.  
Although a previous meta-analysis pooled prevalence data and demonstrated a higher 
likelihood of smoking among people with schizophrenia 3, to our knowledge this is the first 
attempt to provide summary estimates of incident risk.  
 
Our finding in relation to schizophrenia in personal active smokers is consistent with 
previous findings that daily tobacco use is associated with an increased risk of a wider group 
of psychotic disorders and an earlier age at onset 33. Incident schizophrenia may represent a 
transition from an earlier at risk state or prodromal period, during which individuals may 
smoke in order to relieve attenuated psychotic symptoms 50, and it is not possible to exclude 
reverse causality from the available data. Nevertheless, as the prevalence of smoking in 
people with schizophrenia is higher compared to other psychiatric disorders 3 51 52, it is 
possible that smoking could be an independent risk factor for schizophrenia, as our results 
would suggest.  
 
The dopamine hypothesis remains an important theory in the pathology of schizophrenia 53;  
nicotine exposure has been proposed as a plausible risk factor for schizophrenia by directly or 
indirectly increasing dopamine release 33. When considering the dose response relationship, 
there was evidence to suggest an increase in risk of schizophrenia as the number of cigarettes 
smoked increased, with heavier smoking associated with greater risk for schizophrenia. 
However, it is worth noting that one study 4 found a reverse effect, in that, at the very least, 
each incremental increase in smoking was associated with a 10% reduction in the risk of 
schizophrenia, and therefore the results should be interpreted with caution.  
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Our finding of a significant association between maternal smoking and risk of schizophrenia 
in offspring is in line with recently reported research. Despite an early meta-analysis 54 of two 
cohort studies 42 43 on maternal smoking and schizophrenia in offspring which found no 
evidence of an association, subsequent studies have suggested there may be an association 
between maternal smoking and psychiatric disorders, including schizophrenia. Benros, et al. 
[55] found that the offspring of mothers with lung cancer had an increased risk of child 
psychiatric disorders and schizophrenia. A recent study with animals suggests that it is 
plausible to consider prenatal tobacco smoke exposure as a risk factor for schizophrenia in 
later life. Zugno, et al. [56] found an increased risk of developing schizophrenia (as measured 
by changes in behaviour and changes in the cholinergic system) in rats exposed to cigarette 
smoke during the gestational period. Furthermore, our findings are consistent with initial 
indications that a range of perinatal factors, such as obstetric complications, may increase the 
risk of psychosis 57. 
 
In our review, two studies 39 49 reported different levels of exposure to prenatal maternal 
smoke and both found that those who had been exposed to heavy prenatal tobacco smoke had 
a significantly increased risk of having schizophrenia compared to those not exposed to 
prenatal tobacco smoke, though there was no evidence of a dose-response relationship. 
However, previous studies have found a dose response relationship between smoking during 
pregnancy and adult intelligence 58 risk of childhood cancer 59, childhood obesity 60 
suggesting that heavy smoking has the greatest risk on the health of the offspring.  
 
The main strength of this systematic review and meta-analysis is the broad and inclusive 
search strategy designed to be as extensive as possible to maximise sensitivity and ensure that 
as many as possible relevant studies were included. However, despite the fact we developed a 
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comprehensive and robust search strategy, there is always the possibility that inappropriate 
indexing may result in a publication being missed. A limitation of this meta-analysis was the 
fact that we combined odds ratios and hazard ratios due to the small number of studies 
included. The presenting risk estimates for odds ratios and hazard ratios were combined in 
the meta-analysis on an assumption of constant risk over time, and acknowledging that, 
despite schizophrenia being a rare disease, the odds ratios will slightly overestimate the true 
relative risk. It is also possible that there is some publication bias, but due to the small 
number of studies, we did not perform tests of funnel plot asymmetry. All but one of the 
studies we assessed relied on self-reported smoking status which has been shown to be a 
good indicator of true smoking status in general 61, but nevertheless may underestimate the 
true extent of smoking particularly in retrospective accounts where women are asked to think 
back to how much they smoked during pregnancy.  
 
The mixed findings could partly be explained by confounding factors. There are likely to be 
risk factors that we were unable to adjust for such as personality, as the personality trait 
neuroticism has been found to show a strong association with both schizophrenia 62 and 
smoking 63. Ethnicity may also be a confounding factor, as one birth cohort study found that 
African Americans had substantially elevated rates of schizophrenia in comparison with 
Caucasians 64. Furthermore, in the UK, there is a substantial body of research showing higher 
incidence of schizophrenia in Black Caribbean and African populations 65. However, no 
studies in our meta-analysis reported, or controlled for ethnicity, so it is unclear whether any 
studies involved African Americans. Another potential confounder is substance abuse, which 
is also a recognised risk factor for schizophrenia 66. Less than half of the studies reported 
controlling for either substance abuse or cannabis use. There are indications of a genetic 
relationship between nicotine dependence and schizophrenia 67 and these shared risk genes 
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may explain the observed association between smoking and schizophrenia. Equally, familial 
confounding may explain some of the observed association between prenatal tobacco 
exposure and schizophrenia risk 48. Maternal adverse life events are proposed to increase the 
risk of psychosis, and may be a confounder 68 69. Additionally, the association may be 
because mothers who smoke are more likely to have children who smoke70 and it is the active 
smoking that causes schizophrenia.  
 
It is also worth noting that, although our study search was not restricted by geographical 
location, all studies were from the European Region (according to the World Health 
Organisation (WHO) regions 71. There were no studies from any of the other five regions 
(African Region, Region of the Americas, South-East Asia Region, Eastern Mediterranean 
Region, Western Pacific Region).  
 
Conclusions   
Although observational studies have their limitations, i.e. we cannot be certain about the 
causal pathways, the results here suggest that it is plausible to consider that tobacco smoking 
is a causal risk factor for schizophrenia, and that there is a dose-response relationship in that 
the risk of schizophrenia increases with the number of cigarettes smoked. We also found 
evidence that heavy maternal smoking is a risk factor for schizophrenia in offspring. 
Identifying smoking as a potential modifiable risk factor is an important development for the 
field, however due to the small number of studies and the conflicting individual results, 
further longitudinal studies, particularly from regions outside of Europe, are required to 
determine the extent of the risk.  
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